Zai Lab Performance degli utili passati
Criteri Il passato verificati 0/6
Zai Lab ha registrato una crescita degli utili a un tasso medio annuo di 26.2%, mentre il settore Biotechs ha registrato utili in crescita a un tasso medio annuo di 34.1%. I ricavi sono stati in crescita a un tasso medio annuo di 26.6%.
Informazioni chiave
26.16%
Tasso di crescita degli utili
29.29%
Tasso di crescita dell'EPS
| Biotechs Crescita del settore | 17.04% |
| Tasso di crescita dei ricavi | 26.55% |
| Rendimento del capitale proprio | -31.01% |
| Margine netto | -41.86% |
| Ultimo aggiornamento sugli utili | 30 Jun 2026 |
Aggiornamenti sulle prestazioni recenti
Recent updates
Aggiornamento narrativa • Aug 22
ZLAB: Global Immunology And Oncology Pipeline Progress Will Support Future Upside
Analysts have trimmed their fair value estimate for Zai Lab to about $48 from $55. Some Street research points to a higher $45 price target that reflects a shift in focus toward a broader global innovation story.Seeking Alpha • Aug 19
Zai Lab: Revenue Growth And Zoci's Upside Optionality
Summary ZLAB has grown from a Greater China licensing platform into a dual-engine biopharma. They have a growing proprietary global pipeline with KarXT and TIVDAK. And management expects product sales to stabilize during 2H2026. Zoci's SCLC and NEC activity looks promising, while their other partnered combo therapies could expand their indications across other treatments. The main caveat is that ZLAB is already trading at higher valuation multiples compared to its peers. However, in the long run, ZLAB's growth should help justify its current premium, which is why I remain bullish on the shares despite their inherent clinical risks. Read the full article on Seeking AlphaArticolo di analisi • Aug 10
Zai Lab Limited (NASDAQ:ZLAB) Just Reported And Analysts Have Been Cutting Their Estimates
Zai Lab Limited ( NASDAQ:ZLAB ) just released its quarterly report and things are looking bullish. Results overall were...
Aggiornamento narrativa • Aug 07
ZLAB: Global Pipeline Progress And Regulatory Milestones Will Shape A Measured Re Rating
Zai Lab’s updated analyst price target has moved from $21.80 to $24.25. Analysts cite the company’s shift from a China-focused commercial story to a broader global innovation profile as a key driver in their revised view.
Aggiornamento narrativa • Jun 18
ZLAB: DLL3 Program And China Approval Will Drive Long-Term Upside
The analyst price target for Zai Lab has been adjusted slightly lower to $33.30 from $33.78, with analysts citing incremental updates to fair value estimates, the discount rate, revenue growth, profit margin, and future P/E assumptions. What’s in the News for Zai Lab Zai Lab received approval from China’s National Medical Products Administration for TIVDAK to treat adult patients with recurrent or metastatic cervical cancer whose disease progressed after chemotherapy, supported by overall survival data from the Phase 3 innovaTV 301 trial (primary news, NMPA filing).Articolo di analisi • Jun 16
Zai Lab (ZLAB) Stock Could Be 47.5% Undervalued After China Approved TIVDAK
Zai Lab (ZLAB) stock is in focus after China’s National Medical Products Administration approved TIVDAK for adults with recurrent or metastatic cervical cancer whose disease progressed on or after chemotherapy. See our latest analysis for Zai Lab. The NMPA approval for TIVDAK comes after a mixed stretch for Zai Lab, with the stock showing a 1-day share price return of 3.87% and a 7-day share price return of 7.58%, yet a 1-year total shareholder return that declined 56.36%. This suggests...Aggiornamento narrativa • Jun 03
ZLAB: DLL3 Combinations And Fast Track Designation Will Support Long-Term Expansion
Analysts have reduced their price target on Zai Lab by $7, reflecting updated views on fair value, discount rates, growth assumptions, margins, and future P/E expectations following recent research. What's in the News President and COO Josh Smiley plans to leave Zai Lab effective May 22, 2026, as part of a broader leadership reshuffle related to operational efficiency efforts and preparations for the launch of COBENFY in China and several oncology data readouts in 2026, according to recent company announcements.Articolo di analisi • May 11
Zai Lab Limited (NASDAQ:ZLAB) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
It's been a sad week for Zai Lab Limited ( NASDAQ:ZLAB ), who've watched their investment drop 12% to US$18.60 in the...Aggiornamento narrativa • May 01
ZLAB: Diversified Pipeline And DLL3 Partnerships Will Support Long-Term Expansion
The analyst price target for Zai Lab has been reduced by about $14 to $35, with analysts citing lower modeled revenue growth, modestly higher discount rates, and management's commentary on more modest 2026 top line expectations given pricing pressures and competition in China. Analyst Commentary Recent Street research on Zai Lab points to a more cautious stance on revenue growth and valuation, with several firms trimming their price targets while still recognizing areas of execution strength and pipeline potential.Aggiornamento narrativa • Apr 16
ZLAB: Cautious China Outlook And Pipeline Progress Will Shape A Measured Re Rating
Analysts have lowered their average price targets on Zai Lab by several dollars, citing more cautious expectations for 2026 revenue growth. Management anticipates modest top line trends with pricing pressure and rising competition in China, which is reflected in slightly adjusted P/E assumptions and growth inputs.Aggiornamento narrativa • Apr 02
ZLAB: Mixed Coverage And Pipeline Progress Will Shape A Measured Re Rating
Analysts have trimmed their price targets on Zai Lab, and the model update now points to a fair value of $21.80. This reflects expectations for more modest revenue growth and profit margins, along with a higher future P/E multiple.Aggiornamento narrativa • Mar 19
ZLAB: China Approvals And Oncology Pipeline Progress Will Support Future Upside Potential
Analysts have trimmed their price targets on Zai Lab by up to $18, reflecting more cautious assumptions on revenue growth and competitive pressures. At the same time, updated models incorporate a higher projected profit margin and a lower future P/E multiple.Aggiornamento narrativa • Mar 04
ZLAB: China Approvals And Pipeline Execution Will Support Future Upside Potential
Narrative Update The updated analyst price target for Zai Lab has moved down from $67.22 to $55.00 as analysts factor in more modest projected revenue growth, lower profit margins, a higher assumed discount rate, and recent Street research pointing to pricing pressure, competition in China, and adjustments to company models following management commentary. Analyst Commentary Recent Street research on Zai Lab shows a mix of recalibrated price targets and ongoing constructive views on execution and longer term growth prospects.Aggiornamento narrativa • Feb 17
ZLAB: Mixed Coverage And New Approvals Will Shape A Measured Re Rating
Analysts trimmed their price targets on Zai Lab by $3.03, reflecting updated fair value and P/E assumptions, as well as fresh views on the company following recent research coverage changes. Analyst Commentary Recent Street research on Zai Lab has sent a mixed message, with some optimism around longer term potential but also fresh caution on how the current share price lines up with execution risks and valuation assumptions.Aggiornamento narrativa • Feb 03
ZLAB: Fresh Coverage And Pipeline Progress Will Support A Re Rating
The updated analyst price target for Zai Lab moves to about US$23.45 from about US$28.14, as analysts factor in lower revenue growth assumptions and a lower future P/E multiple, partly offset by higher projected profit margins and supported by fresh coverage and a US$35 target from recent Street research. Analyst Commentary While the updated blended price target for Zai Lab sits around US$23.45, investor sentiment is being pulled in different directions.Aggiornamento narrativa • Jan 20
ZLAB: Pipeline And New China Approvals Will Drive Future Upside Potential
Analysts have nudged their fair value estimate for Zai Lab to US$67.22 per share, reflecting slightly updated assumptions on discount rate, revenue growth, profit margin, and future P/E following fresh coverage initiation and list changes in recent Street research. Analyst Commentary Street research on Zai Lab has been mixed recently, but the latest fair value update and fresh coverage suggest that some bullish analysts still see room for upside relative to current pricing.Aggiornamento narrativa • Jan 06
ZLAB: Pipeline Execution After Conviction List Removal Will Drive Upside Potential
Analysts have trimmed their fair value estimate for Zai Lab from US$74.00 to US$67.22, citing updated assumptions for discount rates, revenue growth, profit margins and future P/E multiples following its removal from a regional conviction list by a major broker. Analyst Commentary Goldman Sachs removed Zai Lab from its APAC Conviction List as part of a broader monthly review, which has prompted some investors to reassess expectations and risk appetite around the stock.Aggiornamento narrativa • Dec 20
ZLAB Removed From Conviction List Yet Future Pipeline Progress May Re-Rate Shares
Analysts have cut their price target on Zai Lab from approximately $39 to about $28, reflecting a materially lower growth outlook and higher perceived risk, as evidenced by its recent removal from a major APAC conviction list. Analyst Commentary Bearish analysts have interpreted the removal of Zai Lab from a major APAC conviction list as a signal that the company may face a more challenging path to justifying a premium valuation, particularly given rising competition and execution uncertainties in its pipeline and commercialization strategy.Aggiornamento narrativa • Dec 06
ZLAB: Diversified Pipeline Is Expected To Drive Long-Term Market Expansion
Narrative Update on Zai Lab Analysts have moderately lowered their price target on Zai Lab to approximately $49.49, reflecting more conservative assumptions for revenue growth and profit margins, along with the stock’s recent removal from a key regional conviction list. Analyst Commentary Recent research updates on Zai Lab have prompted a more nuanced view of the company’s risk and reward profile, with analysts highlighting both supportive fundamentals and execution challenges that could influence the stock’s re-rating trajectory.Aggiornamento narrativa • Nov 22
ZLAB: Pipeline Diversification And Ongoing Partnerships Will Support Long-Term Market Expansion
Zai Lab's analyst price target has been revised downward from approximately $53.40 to $49.49. Analysts cite concerns over slowing revenue growth and narrowing profit margins.Articolo di analisi • Nov 09
Zai Lab Limited (NASDAQ:ZLAB) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Zai Lab Limited ( NASDAQ:ZLAB ) missed earnings with its latest third-quarter results, disappointing overly-optimistic...Articolo di analisi • Nov 07
Analyst Forecasts Just Became More Bearish On Zai Lab Limited (NASDAQ:ZLAB)
Market forces rained on the parade of Zai Lab Limited ( NASDAQ:ZLAB ) shareholders today, when the analysts downgraded...Aggiornamento narrativa • Nov 07
ZLAB: Future Product Launches Will Drive Broader Market Reach And Patient Access
Analysts have lowered their price target for Zai Lab from approximately $55.41 to $53.40. They cite adjustments in key financial projections and the company's recent removal from a major conviction list as supporting factors.Articolo di analisi • Nov 06
Revenues Working Against Zai Lab Limited's (NASDAQ:ZLAB) Share Price Following 26% Dive
Zai Lab Limited ( NASDAQ:ZLAB ) shareholders that were waiting for something to happen have been dealt a blow with a...Articolo di analisi • Oct 05
Is Zai Lab (NASDAQ:ZLAB) Using Debt Sensibly?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Aggiornamento narrativa • Sep 23
Expanding China Healthcare And Global Pipelines Will Broaden Patient Options
Despite encouraging Phase III trial data for bemarituzumab in gastric cancer, which bolsters near-term commercial outlooks and regulatory momentum in China, Zai Lab’s consensus analyst price target saw only a slight downward adjustment from $56.31 to $55.41. Analyst Commentary Positive Phase III FORTITUDE-101 trial data for bemarituzumab in first-line FGFR2b+ gastric cancer.Articolo di analisi • Jun 16
Revenues Not Telling The Story For Zai Lab Limited (NASDAQ:ZLAB) After Shares Rise 33%
Zai Lab Limited ( NASDAQ:ZLAB ) shares have had a really impressive month, gaining 33% after a shaky period beforehand...
Nuova narrativa • Apr 30
New VYVGART And Pipeline Advances Will Expand Global Markets
Strong revenue growth is expected due to robust product launches and pipeline innovations, with profitability anticipated through cost optimization and operational efficiencies.Seeking Alpha • Mar 20
Zai Lab: Still Attractive Despite Higher Costs And Added Trade War Risks
Summary ZLAB’s Vyvgart revenue has been impressive, rising from roughly $93.6 million in 2024. I now consider this IP one of ZLAB’s main growth drivers. ZLAB’s ongoing strategy of focusing on Chinese approvals continues to pay off with Vyvgart Hytrulo, Xacduro, and Augtyro in oncology and autoimmune diseases. They also have late-stage assets like Bemarituzumab (gastric cancer), KarXT (schizophrenia), and Optune (pancreatic/lung cancer) that could become major revenue verticals in China. ZLAB’s balance sheet is pretty solid, with close to 2.4 years of runway, and aiming towards profitability by yearend 2025. ZLAB’s valuation is higher than when I first covered it. New trade risks between the US and China also exist, but I remain bullish at these levels. Read the full article on Seeking AlphaArticolo di analisi • Mar 06
Zai Lab Limited's (NASDAQ:ZLAB) 31% Share Price Surge Not Quite Adding Up
Zai Lab Limited ( NASDAQ:ZLAB ) shareholders have had their patience rewarded with a 31% share price jump in the last...Articolo di analisi • Jan 20
Investors Don't See Light At End Of Zai Lab Limited's (NASDAQ:ZLAB) Tunnel
You may think that with a price-to-sales (or "P/S") ratio of 7.9x Zai Lab Limited ( NASDAQ:ZLAB ) is a stock worth...Seeking Alpha • Dec 26
Zai Lab: Rapidly Improving Outlook Bodes Well For The Future
Summary Zai Lab Limited is transitioning from a "Hold" to a "Buy" rating due to rapid revenue growth and upcoming potential approvals. ZLAB's strategy involves in-licensing U.S.-approved drugs for the Chinese market, with key products like Zejula, Qinlock, Nuzyra, Vyvgart, and Optune driving revenue. Despite high costs, ZLAB's consistent quarterly revenue growth and a strong cash position indicate a promising future. Zai Lab's unique market position and strong pipeline make it a compelling investment for those with high risk tolerance. Read the full article on Seeking AlphaArticolo di analisi • Nov 15
The Zai Lab Limited (NASDAQ:ZLAB) Third-Quarter Results Are Out And Analysts Have Published New Forecasts
There's been a notable change in appetite for Zai Lab Limited ( NASDAQ:ZLAB ) shares in the week since its...Articolo di analisi • Sep 28
Zai Lab Limited (NASDAQ:ZLAB) Stock Catapults 26% Though Its Price And Business Still Lag The Industry
Zai Lab Limited ( NASDAQ:ZLAB ) shares have continued their recent momentum with a 26% gain in the last month alone...Articolo di analisi • Sep 23
Zai Lab (NASDAQ:ZLAB) Has Debt But No Earnings; Should You Worry?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Articolo di analisi • Jun 12
Shareholders May Not Be So Generous With Zai Lab Limited's (NASDAQ:ZLAB) CEO Compensation And Here's Why
Key Insights Zai Lab will host its Annual General Meeting on 18th of June Salary of US$868.5k is part of CEO Samantha...Ripartizione dei ricavi e delle spese
Ripartizione dei ricavi e delle spese
Come Zai Lab guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.
Storico di utili e ricavi
| Data | Ricavi | Utili | Spese G+A | Spese di R&S |
|---|---|---|---|---|
| 30 Jun 26 | 450 | -188 | 281 | 0 |
| 31 Mar 26 | 453 | -178 | 279 | 0 |
| 31 Dec 25 | 460 | -176 | 278 | 0 |
| 30 Sep 25 | 442 | -207 | 287 | 0 |
| 30 Jun 25 | 428 | -213 | 284 | 0 |
| 31 Mar 25 | 418 | -252 | 293 | 0 |
| 31 Dec 24 | 399 | -257 | 299 | 0 |
| 30 Sep 24 | 356 | -271 | 299 | 0 |
| 30 Jun 24 | 323 | -298 | 300 | -110 |
| 31 Mar 24 | 291 | -339 | 288 | 0 |
| 31 Dec 23 | 267 | -335 | 282 | 0 |
| 30 Sep 23 | 263 | -301 | 271 | 0 |
| 30 Jun 23 | 252 | -393 | 269 | 110 |
| 31 Mar 23 | 231 | -410 | 264 | 0 |
| 31 Dec 22 | 215 | -443 | 259 | 0 |
| 30 Sep 22 | 197 | -593 | 257 | 0 |
| 30 Jun 22 | 182 | -529 | 249 | 0 |
| 31 Mar 22 | 171 | -554 | 240 | 0 |
| 31 Dec 21 | 144 | -704 | 219 | 0 |
| 30 Sep 21 | 115 | -569 | 190 | -160 |
| 30 Jun 21 | 87 | -537 | 159 | -102 |
| 31 Mar 21 | 61 | -454 | 128 | -34 |
| 31 Dec 20 | 49 | -269 | 111 | 0 |
| 30 Sep 20 | 39 | -239 | 93 | 192 |
| 30 Jun 20 | 29 | -240 | 83 | 185 |
| 31 Mar 20 | 19 | -201 | 74 | 146 |
| 31 Dec 19 | 13 | -195 | 70 | 0 |
| 30 Sep 19 | 8 | -212 | 58 | 166 |
| 30 Jun 19 | 4 | -181 | 45 | 145 |
| 31 Mar 19 | 2 | -160 | 33 | 132 |
| 31 Dec 18 | 0 | -139 | 22 | 120 |
| 30 Sep 18 | 0 | -89 | 14 | 74 |
| 30 Jun 18 | 0 | -67 | 14 | 53 |
| 31 Mar 18 | 0 | -59 | 13 | 46 |
| 31 Dec 17 | 0 | -50 | 12 | 39 |
| 30 Sep 17 | 0 | -50 | 10 | 41 |
| 30 Jun 17 | 0 | -50 | 8 | 44 |
| 31 Mar 17 | 0 | -44 | 7 | 38 |
| 31 Dec 16 | 0 | -38 | 6 | 32 |
Guadagni di qualità: ZLAB al momento non è redditizia.
Margine di profitto in crescita: ZLAB al momento non è redditizia.
Flusso di cassa libero e analisi degli utili
Analisi della crescita degli utili nel passato
Andamento degli utili: ZLAB non è redditizia, ma ha ridotto le perdite negli ultimi 5 anni a un tasso pari a 26.2% all'anno.
Accelerare la crescita: Impossibile confrontare la crescita degli utili di ZLAB nell'ultimo anno con la sua media quinquennale poiché al momento non è redditizia
Guadagni vs Settore: ZLAB non è redditizia, il che rende difficile confrontare la crescita dei suoi utili dell'anno passato con il settore Biotechs ( 64.6% ).
Rendimento del capitale proprio
ROE elevato: ZLAB ha un Return on Equity negativo ( -31.01% ), in quanto al momento non è redditizio.
Rendimento delle attività
Rendimento del capitale investito
Scoprire le aziende con forti performance passate
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/09/09 13:28 |
| Prezzo dell'azione a fine giornata | 2026/09/09 00:00 |
| Utili | 2026/06/30 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.
Scoprite il che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Zai Lab Limited è coperta da 36 analisti. 16 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Rebecca Liang | Bernstein |
| Bo Li | BofA Global Research |
| Louise Chen | Cantor Fitzgerald & Co. |